Last reviewed · How we verify
NCT05262660
The Long-term Effect of SAAE and Medical Treatment for Primary Aldosteronism
trial in Primary Aldosteronism in 400 participants. Status unknown.
1 January 2025
Quick facts
| Lead sponsor | First Affiliated Hospital of Chengdu Medical College |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 April 2022 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across China |
Conditions studied
- Primary Aldosteronism — all drugs for Primary Aldosteronism →
Sponsor
First Affiliated Hospital of Chengdu Medical College
Who can join
Adults 18 to 75, any sex, with Primary Aldosteronism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this prospective controlled trial, we aim to determine whether superselective adrenal artery embolization is superior to medical treatment for patients with PA who refuse surgery for medication. Patients age 18 to 75 years with hypertension will be screened for the presence of PA according to Endocrine Society Clinical Practice Guidelines. Patients with confirmed PA are counseled on the treatment option, including adrenalectomy. Those who opt to enroll in the study choice either SAAE or spironolactone (20-60mg daily) therapy (medical group). In both groups, if office blood pressure exceeds 140/90mmHg, amlodipine and terazosin will sequentially be added to the initial therapy form month 1 to year 3. The primary endpoint is the change in blood pressure, and the secondary end point is the change in biochemical outcomes. The Primary Aldosteronism Surgical Outcome criteria are used to classify clinical and biochemical outcomes as complete, partial, or absent success.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Safety and efficacy of alcohol-mediated bilateral adrenal artery embolization in patients with idiopathic hyperaldosteronism: a 6-month follow-up of a randomized controlled trial.
Zhou Y, Liu S, Ji G, Yang C, et al · · 2025 · PMID 40468047 · DOI 10.1038/s41371-025-01032-6
Verify or expand the search:
- PubMed search for NCT05262660
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Aldosteronism
Currently open trials in the same condition.
- NCT07298954 — Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE) · NA · recruiting
- NCT07111351 — Multi-omics Studies of Primary Aldosteronism · recruiting
- NCT07027254 — PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism · NA · recruiting
- NCT06941116 — Steroids-Based Screening for Primary Aldosteronism · recruiting
- NCT06955286 — Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Witho · recruiting
Other First Affiliated Hospital of Chengdu Medical College trials
Trials by the same sponsor.
- NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
- NCT06282107 — Effectiveness and Safety of BiSAAE for Resistant Hypertension. · NA · not yet recruiting
- NCT06228677 — Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization · recruiting
- NCT06392971 — Deep-sea Fish Oil for Prevention of Acute Radiation-induced Esophagitis · Phase 2 · recruiting
- NCT05552300 — Superselective Adrenal Arterial Embolization for Resistant Hypertension · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05262660 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Chengdu Medical College
- Last refreshed: 2 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05262660.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing